Literature DB >> 26088878

Regulation of nonsmall-cell lung cancer stem cell like cells by neurotransmitters and opioid peptides.

Jheelam Banerjee1, Arokya M S Papu John1, Hildegard M Schuller1.   

Abstract

Nonsmall-cell lung cancer (NSCLC) is the leading type of lung cancer and has a poor prognosis. We have shown that chronic stress promoted NSCLC xenografts in mice via stress neurotransmitter-activated cAMP signaling downstream of beta-adrenergic receptors and incidental beta-blocker therapy was reported to improve clinical outcomes in NSCLC patients. These findings suggest that psychological stress promotes NSCLC whereas pharmacologically or psychologically induced decreases in cAMP may inhibit NSCLC. Cancer stem cells are thought to drive the development, progression and resistance to therapy of NSCLC. However, their potential regulation by stress neurotransmitters has not been investigated. In the current study, epinephrine increased the number of cancer stem cell like cells (CSCs) from three NSCLC cell lines in spheroid formation assays while enhancing intracellular cAMP and the stem cell markers sonic hedgehog (SHH), aldehyde dehydrogenase-1 (ALDH-1) and Gli1, effects reversed by GABA or dynorphin B via Gαi -mediated inhibition of cAMP formation. The growth of NSCLC xenografts in a mouse model of stress reduction was significantly reduced as compared with mice maintained under standard conditions. Stress reduction reduced serum levels of corticosterone, norepinephrine and epinephrine while the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and opioid peptides increased. Stress reduction significantly reduced cAMP, VEGF, p-ERK, p-AKT, p-CREB, p-SRc, SHH, ALDH-1 and Gli1 in xenograft tissues whereas cleaved caspase-3 and p53 were induced. We conclude that stress neurotransmitters activate CSCs in NSCLC via multiple cAMP-mediated pathways and that pharmacologically or psychologically induced decreases in cAMP signaling may improve clinical outcomes in NSCLC patients.
© 2015 UICC.

Entities:  

Keywords:  cAMP signaling; cancer stem cell like cells; cancer stem cell markers; neurotransmitters; non small-cell lung cancer; opioid peptides

Mesh:

Substances:

Year:  2015        PMID: 26088878      PMCID: PMC4600645          DOI: 10.1002/ijc.29646

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  59 in total

1.  The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid.

Authors:  H M Schuller; P K Tithof; M Williams; H Plummer
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

2.  Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.

Authors:  Helene Hartvedt Grytli; Morten Wang Fagerland; Sophie D Fosså; Kristin Austlid Taskén; Lise Lund Håheim
Journal:  Prostate       Date:  2012-07-20       Impact factor: 4.104

3.  The sympathetic nervous system induces a metastatic switch in primary breast cancer.

Authors:  Erica K Sloan; Saul J Priceman; Benjamin F Cox; Stephanie Yu; Matthew A Pimentel; Veera Tangkanangnukul; Jesusa M G Arevalo; Kouki Morizono; Breanne D W Karanikolas; Lily Wu; Anil K Sood; Steven W Cole
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

Review 4.  Lung cancer stem cells and implications for future therapeutics.

Authors:  Jing Wang; Ze-hong Li; James White; Lin-bo Zhang
Journal:  Cell Biochem Biophys       Date:  2014-07       Impact factor: 2.194

5.  Neuroendocrine lung carcinogenesis in hamsters is inhibited by green tea or theophylline while the development of adenocarcinomas is promoted: implications for chemoprevention in smokers.

Authors:  Hildegard M Schuller; B Porter; A Riechert; K Walker; R Schmoyer
Journal:  Lung Cancer       Date:  2004-07       Impact factor: 5.705

Review 6.  Worldwide trend of increasing primary adenocarcinoma of the lung.

Authors:  Haruhiko Nakamura; Hisashi Saji
Journal:  Surg Today       Date:  2013-06-11       Impact factor: 2.549

7.  Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.

Authors:  Silvia Licciulli; Jacqueline L Avila; Linda Hanlon; Scott Troutman; Matteo Cesaroni; Smitha Kota; Brian Keith; M Celeste Simon; Ellen Puré; Fred Radtke; Anthony J Capobianco; Joseph L Kissil
Journal:  Cancer Res       Date:  2013-08-13       Impact factor: 12.701

8.  beta-Carotene promotes the development of NNK-induced small airway-derived lung adenocarcinoma.

Authors:  Hussein A N Al-Wadei; Hildegard M Schuller
Journal:  Eur J Cancer       Date:  2009-02-28       Impact factor: 9.162

9.  A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1.

Authors:  Makoto R Hara; Jeffrey J Kovacs; Erin J Whalen; Sudarshan Rajagopal; Ryan T Strachan; Wayne Grant; Aaron J Towers; Barbara Williams; Christopher M Lam; Kunhong Xiao; Sudha K Shenoy; Simon G Gregory; Seungkirl Ahn; Derek R Duckett; Robert J Lefkowitz
Journal:  Nature       Date:  2011-08-21       Impact factor: 49.962

10.  Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.

Authors:  N Kuzumaki; A Suzuki; M Narita; T Hosoya; A Nagasawa; S Imai; K Yamamizu; H Morita; H Nagase; Y Okada; H J Okano; J K Yamashita; H Okano; T Suzuki; M Narita
Journal:  Br J Cancer       Date:  2012-02-16       Impact factor: 7.640

View more
  11 in total

1.  Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer.

Authors:  Hildegard M Schuller
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 2.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

3.  Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.

Authors:  Monique B Nilsson; Huiying Sun; Lixia Diao; Pan Tong; Diane Liu; Lerong Li; Youhong Fan; Alissa Poteete; Seung-Oe Lim; Kathryn Howells; Vincent Haddad; Daniel Gomez; Hai Tran; Guillermo Armaiz Pena; Lecia V Sequist; James C Yang; Jing Wang; Edward S Kim; Roy Herbst; J Jack Lee; Waun Ki Hong; Ignacio Wistuba; Mien-Chie Hung; Anil K Sood; John V Heymach
Journal:  Sci Transl Med       Date:  2017-11-08       Impact factor: 17.956

4.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

Review 5.  β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.

Authors:  Monique B Nilsson; Xiuning Le; John V Heymach
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-11       Impact factor: 4.147

Review 6.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

7.  GABAA receptor agonist suppresses pediatric medulloblastoma progression by inhibiting PKA-Gli1 signaling axis.

Authors:  Itishree Kaushik; Sanjay K Srivastava
Journal:  Mol Ther       Date:  2022-03-21       Impact factor: 12.910

8.  Sonic Hedgehog Signaling Pathway Mediates Proliferation and Migration of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis via MAPK/ERK Signaling Pathway.

Authors:  Fang Liu; Xiao Xue Feng; Shang Ling Zhu; Hong Yu Huang; Ying Di Chen; Yun Feng Pan; Rayford R June; Song Guo Zheng; Jian Lin Huang
Journal:  Front Immunol       Date:  2018-12-05       Impact factor: 7.561

9.  Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors.

Authors:  Yingzhuo Xu; Jian Wang; Xu Wang; Xiaoshu Zhou; Jing Tang; Xiaohua Jie; Xijie Yang; Xinrui Rao; Yunhong Xu; Biyuan Xing; Zhenyu Li; Gang Wu
Journal:  Cell Death Discov       Date:  2022-01-24

10.  Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs.

Authors:  Chia-Hao Chang; Chih-Hsin Lee; Jen-Chung Ko; Lih-Yu Chang; Ming-Chia Lee; Jun-Fu Zhang; Jann-Yuan Wang; Jin-Yuan Shih; Chong-Jen Yu
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.